EGFR and non-small cell lung carcinoma: Analysis of non-small cell lung cancer (NSCLC) patients has shown that 70–80% of EGFR/HER1 gene-mutated patients are responsive to TKIs compared with 10–20% of EGFR/HER1 wild-type patients (42).